In recent years, adjuvant pembrolizumab and nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, have been shown to provide durable antitumor activity in advanced mucosal melanoma by tumor-infiltrating T lymphocytes [3]. This evidence concerns the gene PDCD1 and mucosal melanoma.